Tryptophan Metabolism

Tryptophan (Trp) is an essential amino acid metabolized via three competing pathways: the kynurenine pathway, the serotonin pathway, and the microbial indole pathway. The balance among these pathways is profoundly influenced by the gut microbiome, inflammation, and metal cofactors, making tryptophan metabolism a critical node in the gut brain axis and a convergent disruption point across neurological, autoimmune, and metabolic diseases.

The Three Pathways

1. Kynurenine Pathway (~95% of Trp)

The dominant route of tryptophan catabolism, controlled by two iron-dependent rate-limiting enzymes:

  • IDO1/IDO2 (indoleamine 2,3-dioxygenase): Expressed in immune cells and gut epithelium; induced by IFN-gamma and inflammation. Requires heme iron as a cofactor.
  • TDO (tryptophan 2,3-dioxygenase): Expressed primarily in the liver; constitutive. Also requires heme iron.

Downstream metabolites:

  • Kynurenine (KYN): Immunomodulatory; activates the aryl hydrocarbon receptor (AhR).
  • Kynurenic acid (KA): Neuroprotective; NMDA receptor antagonist. Depleted in ASD fecal samples [1].
  • 3-Hydroxykynurenine (3-HK): Neurotoxic; generates free radicals.
  • Quinolinic acid (QUIN): Potent neurotoxin; NMDA receptor agonist and excitotoxin. Elevated in neuroinflammatory conditions.

The KA/QUIN ratio reflects the neuroprotective-neurotoxic balance: inflammation shifts this ratio toward QUIN, driving neuroinflammation.

2. Serotonin Pathway (~1-2% of Trp)

  • TPH1/TPH2 (tryptophan hydroxylase): Rate-limiting enzymes; TPH1 in gut enterochromaffin cells, TPH2 in CNS neurons.
  • Produces 5-hydroxytryptophan (5-HTP) then serotonin (5-HT).
  • ~95% of body serotonin is produced in the gut by enterochromaffin cells, regulated by gut bacteria (Clostridia, spore-forming bacteria).
  • Gut serotonin regulates motility, secretion, and visceral sensation; does not cross the BBB.
  • ASD children show reduced fecal 5-HTP and altered serotonin metabolism [1].

3. Microbial Indole Pathway

Gut bacteria directly metabolize tryptophan to produce indole derivatives:

  • Indole: Produced by tryptophanase (TnaA) in E. coli, Bacteroides, Clostridium, Proteus.
  • Indole-3-propionic acid (IPA): Produced by Clostridium sporogenes; atheroprotective in cardiovascular disease; inversely correlated with arterial plaque size [2].
  • Indole-3-acetic acid (IAA): Produced by multiple genera; AhR ligand.
  • Indole-3-aldehyde (IAld): Produced by Lactobacillus; potent AhR activator driving IL-22 production.
  • Tryptamine: Produced by Clostridium and Ruminococcus; serotonin receptor agonist.

AhR Activation: The Therapeutic Target

Indole derivatives activate the aryl hydrocarbon receptor (AhR) on intestinal epithelial cells, immune cells, and astrocytes:

  • Drives IL-22 production, which strengthens gut barrier integrity and stimulates antimicrobial peptide production.
  • Promotes Treg differentiation and suppresses Th17 responses — directly relevant to multiple sclerosis and autoimmunity.
  • In the CNS, AhR activation on astrocytes is anti-neuroinflammatory [3].
  • However, excessive AhR activation may be pathological: in ASD mouse models (BTBR), elevated indole/IPA hyperactivated AhR, suppressing glutamate transporters and GABA receptors, worsening E/I imbalance [4].

Disease Relevance

Autism Spectrum Disorder

  • Fecal kynurenate, indolelactate, and 5-HTP all significantly lower in ASD children [1].
  • Brain activity in insula and cingulate cortex mediates the relationship between indolelactate levels and ASD severity.
  • Faecalibacterium hominis supplementation corrected indole-AhR dysregulation and restored social behavior in BTBR mice [4].
  • Tryptophan metabolite profiles are among the most consistent ASD biomarkers.

Multiple Sclerosis

  • AhR ligand depletion contributes to unchecked Th17-mediated neuroinflammation.
  • Dietary and microbial AhR ligands are therapeutic targets [3].

Depression

  • IDO1 induction by inflammatory cytokines shunts tryptophan away from serotonin toward kynurenine, producing the "serotonin depletion" of inflammatory depression.
  • Quinolinic acid accumulation contributes to NMDA-mediated excitotoxicity in depressive states.

Cardiovascular Disease

  • IPA is atheroprotective; Parabacteroides distasonis (indole-producing) inversely correlated with plaque size [2].

Metal Connections

  • Iron dependence of IDO/TDO: Both rate-limiting kynurenine pathway enzymes require heme iron. Iron dyshomeostasis directly alters the kynurenine/serotonin balance.
  • Metal-induced inflammation upregulates IDO1: Via IFN-gamma induction, metals shift tryptophan catabolism toward the neurotoxic kynurenine arm.
  • Metal-driven dysbiosis reduces indole-producing commensals: Loss of AhR ligand production impairs gut barrier integrity and removes anti-inflammatory signaling [5].
  • The net effect of metal exposure is a triple hit: more neurotoxic QUIN, less serotonin, and fewer protective AhR ligands.

Key Sources

Connections

  • gut brain axis — tryptophan metabolites are key mediators of gut-brain communication
  • neuroinflammation — kynurenine pathway products drive and modulate neuroinflammation
  • short chain fatty acids — co-depleted with indole producers in dysbiosis
  • inflammation — IDO1 induction by inflammation redirects tryptophan catabolism
  • iron — heme iron cofactor for IDO and TDO
  • faecalibacterium prausnitzii — F. hominis corrects indole-AhR dysregulation in ASD models
  • autism spectrum disorder — tryptophan metabolites among most consistent ASD biomarkers
  • multiple sclerosis — AhR ligand depletion contributes to Th17-driven neuroinflammation
  • indoles — indole and indole-3-aldehyde are key tryptophan-derived AhR ligands produced by gut bacteria

References (9)

  1. Lisa Aziz-Zadeh, Sofronia M. Ringold, Aditya Jayashankar et al. (2025). Aziz-Zadeh 2025 — Relationships Between Brain Activity, Tryptophan-Related Gut Metabolites, and Autism Symptomatology. Nature Communications. doi:10.1038/s41467-025-58459-1
  2. Dorothea Katharina Hoffelner, Tim Hendrikx (2025). Emerging therapy targets to modulate microbiome-mediated effects evident in cardiovascular disease. Frontiers in Cardiovascular Medicine. doi:10.3389/fcvm.2025.1631841
  3. V. Martinelli, M. Albanese, M. Altieri et al. (2022). Gut-oriented interventions in patients with multiple sclerosis: fact or fiction?. European Review for Medical and Pharmacological Sciences. doi:10.26355/eurrev_202202_28007
  4. You Yu, Yujing Wang, Jie Zhang et al. (2025). Yu 2025 — The Gut Commensal Faecalibacterium hominis Attenuates Indole-AhR Signaling and Restores ASD-Like Behaviors with BTBR Mice. Frontiers in Microbiology. doi:10.3389/fmicb.2025.1640149
  5. Karen Pendergrass (2026). Heavy Metals, Microbial Metallomics, and the US Obesity Epidemic: A Mechanistic Examination of a Population-Level Metabolic Disruption. Zenodo Preprint. doi:10.5281/zenodo.18434951
  6. Tingting Wang, Beidi Chen, Mingcui Luo et al. (2023). Wang 2023 — Microbiota-Indole 3-Propionic Acid-Brain Axis Mediates Abnormal Synaptic Pruning of Hippocampal Microglia and Susceptibility to ASD in IUGR Offspring. Microbiome. doi:10.1186/s40168-023-01656-1
  7. Federica Gevi, Lello Zolla, Stefano Gabriele et al. (2016). Gevi 2016 — Urinary Metabolomics of Young Italian Autistic Children Supports Abnormal Tryptophan and Purine Metabolism. Molecular Autism. doi:10.1186/s13229-016-0109-5
  8. Pamela Vernocchi, Chiara Marangelo, Silvia Guerrera et al. (2023). Vernocchi 2023 — Gut Microbiota Functional Profiling in ASD: Bacterial VOCs and Related Metabolic Pathways Acting as Disease Biomarkers and Predictors. Frontiers in Microbiology. doi:10.3389/fmicb.2023.1287350
  9. Yuanpeng Zheng, Marie K. Bek, Naika Z. Prince et al. (2021). Zheng 2021 -- The Role of Bacterial-Derived Aromatic Amino Acids Metabolites Relevant in Autism Spectrum Disorders: A Comprehensive Review. Frontiers in Neuroscience. doi:10.3389/fnins.2021.738220